Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
February 21, 2024 at 01:18 am EST
Share
Genomma Lab Internacional, S.A.B. de C.V. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was MXN 3,524.74 million compared to MXN 4,132.23 million a year ago. Net loss was MXN 115.5 million compared to net income of MXN 245.99 million a year ago.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
